Comments
The Delhi High Court on Monday set aside the Centre’s notification banning the manufacturing and sale of Wockhardt’s anti-inflammatory medicine ‘Ace Proxyvon’, used in painful rheumatic conditions.
Justice Vibhu Bakhru remanded the matter to the Drugs Technical Advisory Board (DTAB) / sub-committee constituted by the Centre to examine the issue regarding the fixed dose combination (FDC) drug Ace Proxyvon in accordance with the directions earlier issued by the Supreme Court.
Wockhardt had challenged the notification on several grounds, including that it was issued in violation of principles of natural justice, it was based on the recommendations of the sub-committee of DTAB, which has been made without application of mind.
The firm had claimed that the notification was passed without following the earlier directives of the Supreme Court and the FDC has a sound therapeutic justification and poses no risk to human beings.
The high court in its judgment said the sub-committee was to provide comprehensive material for enabling the government to take such decision.
It said the court was of the view that the notification “cannot be sustained” and it is “set aside“.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.